United Therapeutics Corporation (UTHR) Stock: Price, Forecast & Analyst Target
United Therapeutics Corporation (UTHR) — MoonshotScore 97/100 (Exceptional band), calculated Nov 18, 2026. Price $577.34 (-1.16%), as of the Nov 18, 2026 trading session; market cap $24.6B.
Educational signal · not a buy or sell recommendation · How to read this
United Therapeutics Corporation · UTHR · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12: United Therapeutics is a profitable commercial drugmaker centered on pulmonary hypertension therapies, with Tyvaso contributing far more revenue than any other product. Tyvaso’s ability to extend into broader lung disease indications while preserving cash generation will determine whether the recent revenue plateau is temporary or a harder limit.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · United Therapeutics (UTHR)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 4 of the last 8 reports
- Altman Z 22.92 · Piotroski F 7
- ROE 19.1% · ROA 10.9% · current ratio 4.61
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 97 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $577.34 | |
| Change on the day | -1.16% | |
| 52-week range | $455.63–$614.23 | |
| Market capitalisation | $24.6B | — |
| Price / earnings (trailing) | 20.45 | |
| Shares traded on the day | 416.6K | |
| Beta (volatility vs the S&P 500) | 0.56 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for United Therapeutics (UTHR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is United Therapeutics (UTHR), and what does it report?
Short answer · as of
United Therapeutics is already a scaled commercial drug business, not a development-stage biotechnology company awaiting an inaugural product. It sells inhaled, infused and oral therapies for pulmonary vascular disease, alongside Unituxin for high-risk neuroblastoma.
Research dated 2026-09-12.
Reported revenue largely measures sales of named medicines rather than licensing milestones or research partnerships. Tyvaso dominates the product mix, while Remodulin, Orenitram, Unituxin and Adcirca provide smaller revenue streams; this concentration makes patient adoption and indication expansion within the Tyvaso franchise especially consequential.
What do the latest results show for United Therapeutics (UTHR)?
Research dated 2026-09-12.
Revenue edged above the immediately preceding period but remained below the earlier run rate and missed the external estimate. Gross profit, operating profit, net income and diluted earnings rebounded sequentially, while research spending rose and selling and administrative expense declined.
The visible operating mechanism was improved gross profit combined with lower selling and administrative expense, which more than absorbed higher research spending. Management says underlying fundamentals remain strong and expects improved performance later in the year, but the reported revenue series has yet to show that acceleration.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $800M | $339M | $7.16 (diluted) |
| Q4 FY2025 | $790M | $364M | $7.70 (diluted) |
| Q1 FY2026 | $782M | $275M | $5.82 (diluted) |
| Q2 FY2026 | $783M | $333M | $7.27 (diluted) |
What are the financial strengths and risks for United Therapeutics (UTHR)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
United Therapeutics carries no debt, holds cash and investments well above total liabilities, and has produced positive operating cash flow throughout the displayed quarterly series. High gross and operating margins give the company unusual capacity to fund research and capital spending internally.
Cash and short-term investments declined across the broader reported window before recovering sharply in the latest periods; long-term investments add another layer to the reserve. Capital spending remains substantial and operating cash flow can vary meaningfully between periods, so the direction of free cash generation matters more than any isolated quarter.
Tyvaso concentration is the sharper business risk. A demand setback, launch delay or regulatory constraint affecting that franchise would strike the product that funds much of the company’s research agenda, while the remaining medicines are not yet large enough to replace it readily.
What should you watch next at United Therapeutics (UTHR)?
Short answer · as of
Current published price targets run low $368.00 · high $850.00 · consensus $671.73 · median $703.00 against a quoted price of $577.34 (as of Nov 18, 2026).
Research dated 2026-09-12.
Revenue breaking above its recent plateau without sacrificing earnings resilience would provide the clearest near-term evidence of renewed momentum. The pending consensus expects revenue near the recent run rate and earnings below the latest result, while recent history shows revenue expectations have been harder to clear consistently than earnings expectations.
Tyvaso-specific evidence deserves greater weight than consolidated guidance: launch trajectory, uptake in broader lung disease, and the regulatory path for DPI and SMI formulations. Management says an IPF launch would begin with nebulized Tyvaso and that further FDA engagement is required for the other delivery formats.
Longer-range consensus assumes accelerating revenue and earnings, but the spread between revenue estimates widens materially farther out. Operating cash flow, capital spending and the durability of the recent cash recovery offer practical checks on whether commercial expansion is translating into additional financial capacity.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does United Therapeutics compare with its peers?
Short answer
United Therapeutics's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
United Therapeutics has the margins, recurring profit, cash generation and debt-free balance sheet associated with a mature specialty pharmaceutical company. Its product concentration, however, remains closer to a focused biotechnology business: Tyvaso carries far more economic weight than the rest of the portfolio.
That combination changes the comparison. United Therapeutics is not chiefly dependent on outside financing to reach its next clinical or regulatory milestone, yet its growth profile still depends heavily on expanding a particular pulmonary franchise across indications and delivery formats.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| United Therapeutics (UTHR) — this page | $577.34 | $24.6B | 97 |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $941.25 Nov 18, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $259.52 Nov 18, 2026 | $28.6B | 74 5-pillar Nov 18, 2026 | |
| $68.67 Nov 18, 2026 | $39.5B | 73 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $368.00 – $850.00
- Consensus target
- $671.73
- Median target
- $703.00
Consensus record · Captured .
Measured against a quoted price of $577.34 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 13, 2026
- Transactions
- 60
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 52
- Other transactions
- 8
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held UTHR in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.30% | $67.95M | Added +12.6% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about United Therapeutics (UTHR)?
What Investors Ask About United Therapeutics (UTHR) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does Tyvaso matter so much to United Therapeutics?
Tyvaso generates far more revenue than any other medicine in the portfolio and anchors the company’s pulmonary franchise. Its adoption across approved uses and potential expansion into additional lung disease indications therefore have an outsized effect on companywide growth.
How will nebulized Tyvaso differ from Tyvaso DPI in the IPF launch?
Management says the IPF launch would begin with nebulized Tyvaso. DPI and SMI would require further FDA engagement before those delivery formats could join that indication.
What roles do Remodulin and Orenitram play beside Tyvaso?
Remodulin delivers treprostinil by infusion, while Orenitram provides an oral formulation for pulmonary arterial hypertension. They broaden delivery choice within the pulmonary franchise and contribute meaningful revenue, though neither approaches Tyvaso’s scale.
Why is Unituxin different from United Therapeutics’ pulmonary medicines?
Unituxin is a monoclonal antibody used for high-risk neuroblastoma, making it the commercial portfolio’s oncology outlier. It diversifies disease exposure, but its revenue contribution remains far below Tyvaso’s.
What is the UTHR stock price today?
The last price recorded for United Therapeutics Corporation (UTHR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the UTHR price target?
The analyst consensus price target for United Therapeutics Corporation (UTHR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold UTHR
Funds in our ETF coverage that list UTHR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Invesco S&P MidCap Quality ETF (XMHQ) | 3.48% | |
| JPMorgan Small & Mid Cap Enhanced Equity ETF (JMEE) | 0.68% |